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ObjectMs
. This study was designed to assess the safety and
efficacy of intravenously administered sonicated human serum
albumin for enhancing echocardlographic delineation of the left
ventricular endocardlum and improving assessment of wall mo-
tion In patients with Incomplete depiction of noncontrast echocar-
di phy .
Background. Echocardiographic regional wall motion analysis
is Impaired by incomplete en
ial definition in as many as
10% of patients. Sonicated human serum albumin is a stable
contrast material that, unlike other agents, opacifles the left
ventricle when administered intravenously
.
Methods. One hundred seventy-five patients were enrolled at
eight centers on the basis of incomplete echocardiographic endol
al depiction. Sonlcated 5% human serum albumin, a stable
preparation of air-filled microspheres (size range I to 10
), was
administered Intravenously in divided doses : 0.08 g body
weight in all patients, followed by 0 .14 and 0.08 mlkg or a single
Determination of global and regional left ventricular systolic
performance is a central element Is, the evaluation and
treatment of patients with known or suspected heart disease .
Two-dimensional echocardiography provides high resolution
im
ing of the left ventricle and enables detailed assessment
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dose of 0.22 milkg, depending on the result of the initial dose.
Investigators and independent reviewers blinded to the protocol
scored the echocardiograms for degree of lestft ventricular opacifi
cation and improvement of end ardiai border depiction
.
Results. Overall, 81% of patients had at least moderate left
ventricular chamber opacification with at least one contrast dose,
and endocardial definition was improved in 83% . In the subgroup
with inadequate left ventricular opacification from the initial dose,
a second, larger dose (0
.22 mllkg) improved endocardial depiction
in 64%. No signincant side effects occurred .
Conclusions. In patients with incomplete ech rdiographic
endocardial definition, sonicated human serum albumin is a safe,
effective contrast agent that, when administered intravenously,
produces left ventricular chamber opacification, improves endo-
cordial depiction and enhances regional wall motion analysis .
(J Am Coll C of 1993;22:1494-1500)
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of regional wall motion . However, acoustic impedance
caused by body habitus and lung disease results in "inade-
quate" echocardiograms in - 10% of patients in a large series
(1-3), based on incomplete imaging of ventricular myocar-
dium and endocardium . As a means to enhance imaging of
the left ventricle, several echocardiographic contrast agents,
including Renografin (4), saccharide microparticles (5,6) and
hand-prepared albumin microspheres (7), have been evalu-
ated, but these have met with limited reproducibility of the
contrast effect and product inconsistency, and none has been
able to traverse the pulmonary vascular bed . A new contrast
agent, a stable preparation of air-filled microspheres created
by sonication of human serum albumin, is capable of
transpulmonary passage, permitting left heart opacification
from an intravenous injection . The purpose of this study was
to evaluate the safety and efficacy of the intravenous admin-
istration of this contrast agent as a means to opacify the left
ventricular cavity and, thereby, to enhance endocardial
border definition in patients with incomplete depiction on
baseline aoncontrast echocardiography .
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Table 1 . Patient Demographics
values presented are mean value ± SD or number M1 . 1IA -= transient
ischemic attack .
Mellds
Study patients. One hundred seventy-five patients (122
men and 53 women, 23 to 78 years old [mean 561) were
enrolled at eight investigating centers . Initially, patients
were considered if, in the qualitative estimation of the
investigator, at least 20% of the left ventricular endocardium
was not clearly depicted on the baseline echocardiogram
obtained within 10 days of study entry . However, subse-
quent enrollment required inadequate depiction of at least
two of the six endocardial segments into which the baseline
two- or four-chamber echocardiogram was divided. Demo-
graphic, clinical, and historical features of the study group
are described in Table 1 . The study protocol was approved
by the appropriate review board at each institution, and
informed consent was obtained from each patient . Exclusion
criteria included history of blood product hypersensitivity
;
lactation or pregnancy (a negative response on a pregnancy
test was required within 48 h before contrast medium admin-
istration in women of child-bearing potential)
; patient's
presence in an intensive care setting or receipt of mechanical
ventilatory support ; and mental incompetence or inability to
follow instructions .
Contrast agent. The echocardiographic contrast material
consisted of a preparation of air-filled microspheres created
by sonication of 5% human serum albumin solution (Al-
bunex, Molecular Biosystems, Inc .) . Microspheres in this
preparation range in size from 1 to 10 lim (mean particle size
4 lkm, 95% of particles <10 ILm), permitting free passage
through the pulmonary capillary circulation . There are 4 x
108 microspheres/ml of solution .
Study protocol . On enrollment, demographic and medical
historical information was collected . On the day of the
procedure, baseline blood samples were obtained for blood
chemistry and hematologic studies . Physical examination
CROUSE ET AL .
	
1495
ALBUNEX ENPOUCARDiAL BORDER DELINEATION STUDY
was performed, and a 12-lead electrocardiogram (ECG) was
recorded just before the study . Two-dimensional echocardi-
ography was repeated on the day of the study in the apical
two- or four-chamber view, or both, to confirm endocardial
dropout in at least two of six endocardial segments
.
After baseline measurements, recordings and information
were obtained, a standard intravenous infusion of either 5%
dextrose in water or 0 .9% saline solution was established
using a >20-gauge cannula, usually positioned in the right
antecubital vein . Patients were then positioned either supine
or in the left lateral decuhitus position . Echocardiograms
were recorded on videocassette tapes using the standard
apparatus at each center . Ultrasound settings were opti-
mized for each patient to provide the best possible noncon-
trast echocardiogram, and these settings were used without
further adjustment throughout the study . Imaging was initi-
ated just before contrast agent administration and continued
for 2 to 3 min after each injection to ensure complete
clearance of contrast agent before subsequent injections .
A series of either two or three contrast agent irieclions
were administered in each patient, with the number of
injections determined by the degree of left ventricular opaci-
fication observed with the first dose . Injections were sepa-
rated by 5-min intervals, and the total dose administered in
each patient was 0 .3 ml/kg body weight . An initial dose of
0.08 ml/kg was administered in all patients . If intermediate or
greater left ventricular chamber opacification was observed
by the investigator after this initial dose (Group A), subse-
quent doses of 0
.14 and 0 .08 ml/kg were administered . If the
initial dose failed to produce this degree of opacification
(Group B), a second and final dose of 0
.22 ml/kg was given .
Each dose was administered at I ml/s, and then the intrave-
nous flush solution was infused at a "wide-open" rate, and
the cannulated arm was raised to a semivertical position for
10 s after injection to augment venous return .
The recorded images were evaluated by the investigator
and two independent reviewers . They were graded for
degree of left ventricular chamber opacification and im-
provement of epdocardial border definition, according to the
following grading systems .
Grading systems. The degree of left ventricular chamber
opacification after contrast agent administration was scored
according to the following scale, which was also used to
determine whether patients should receive the two- or three-
dose regimen : 0 = no contrast; I + = faint appearance of
contrast (Fig. 1) ; 1 .5+ = between faint and intermediate
opacification ; 2+ = intermediate opacification (chamber
half-filled) ; 2
.5+ = between intermediate and full chamber
opacification ; 3+ = full chamber opacification (Fig
. 2) .
To assess the effect of contrast agent administration on
endocardial border definition, the left ventricular endocar-
dium was divided into six segments ; the basal, middle and
apical segments of each wall in the two- or four-chamber
view (Fig . 3). The clarity of endocardial imaging for each
segment was scored as A = not well delineated ; B = average
Group A :
Three
Injections
(n 106)
Group B :
Two
Injections
(n 69) Val le
Age (y) 515 14 .1 59 .3 9.6 0-001
Weight (Ib) 188 .6 ± 39.9 202.0 44 .1 0 .039
[kg] [84 .9 ± 18 .01 [90
.9 19 .81
Height (in.) 68 .4 ± 3 .9 68 .5 ± 4.2 NS
[cm) 1173.73 ± 9 .91 [173 .9 10 .7]
% Male 69 (65) 53 (77) NS
Hypertension 64 (60) 49(71) NS
Coronary artery disease 75 (71) 54(78) NS
Arrhythmias 23(22) 16 (23) NS
Intracardiac shunts 3(3) 1 (1) NS
Stroke or TIA 3(3) 1 (1) NS
Pulmonary disease 46 (43) 28(41) NS
Cardiomyopathy 6(6) 1 (1) NS
Valvular heart disease 61 (58) 34(49) NS
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FI uree 1 . A typical two-chamber view at baseline (A) and during
peak contrast enhancement of the left ventricular chamber showing
I+ opacification (g),
delineation; C = good delineation ; D = excellent delinea-
tion .
Improvement of endocardial definition was scored when
the interpreter graded at least one segment as having a
precontrast grade of A or B or better after contrast agent
administration . The mean number of baseline A segments
was compared with the mean number of A segments after
contrast administration using a paired t test . The indepen-
dent reviewers were not informed of the volume or the order
of contrast injections, and the videotapes were reviewed by
them in random order rather than in consecutive order of
dose administration . To test the validity of the scoring
system, studies before and after contrast administration
from a subset of 20% of the 175 patients were assessed in the
following manner for the independent reviewers only . In
random order, echocardiograms were graded for degree of
SACC Vol. 22, No. 5
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Figure 2 . A typical two-chamber view at baseline (A) and during
peak contrast enhancement of the left ventricular chamber showing
3+ opacification (8) .
left ventricular char ber opacification and segmental endo-
cardial definition . St idles were not grouped together for an
individual patient or as part of a precontrast versus postcon-
trast comparison . Only after assessment of these randomly
presented studies was complete were the data organized by
patient to assess the changes in opacification and delinea-
tion. The observations from this subset were compared with
those in the group as a whole to assess for bias that could be
introduced by foreknowledge of the precontrast versus post-
contrast timing of the study .
Investigators were questioned with regard to their confi-
dence in describing regional wall motion on the basis of the
baseline echocardiogram and again on the basis of the
contrast images . This aspect of evaluating the efficacy of
contrast agent administration reflected a highly subjective
JACC Vol . 22, No. 5
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Figure 3. Schematic of left ventricular endocardial borders that
were graded in the apical two- and four-chamber echocardiographic
views . LA
= left atrium, LV = left ventricular
; RA = right atrium ;
RV = right ventricular .
assessment sment by the investigators and was not subjected to
statistical analysis .
Videodensitometry . Videodensitometry (quantitation of
pixel density) was performed to determine whether the
subjective: visual grading score, which is partially based on
perceived brightness, correlated with an objective evalua-
tion of the degree of brightness in the image . A random
sample of I I study videotapes, representing 28 different
contrast echocardiograms, was analyzed . An image from
each contrast echocardiogram was graded by the investiga-
tor and the two independent reviewers. Two images (a precon-
trast image and the same contrast image graded by the inves-
tigator) were digitized from each echocardiogram on the
videotape into an off line computer analysis system (GTI
Freeland) . An independent reviewer identified the endocardial
border in these images . In the precontrast image, the reviewer
identified a region within the left ventricular chamber having
the least brightness . Videodensitometry within this region
provided a baseline brightness value
. Correspondingly, in the
contrast images, the reviewer identified a region within the
chamber that had the maximal brightness . The computer
system was used to divide the left ventricular chamber into
three zones and to delineate a small region of interest within
each zone . The normalized videodensity, corrected for the
baseline brightness in the precontrast image, was integrated
over these three regions of interest to derive a value for the
entire chamber in each image .
Safety monitoring . Safety was evaluated by observing
patients for changes in vital signs, physical examination or
12-lead ECG and, by monitoring the development of symp-
toms during the testing and follow-up periods . Patients were
assessed for 30 min after the final dose of contrast agent was
administered and were then discharged from the study site .
Each patient was telephoned the next day to complete a
questionnaire and to determine whether any adverse effects
had occurred. If the patient reported a complaint or an
increase in previously reported symptoms, he or she was
required to return to the study site for a complete evaluation
of blood chemistry and blood counts, physical examination
and 12-lead ECG .
(MOUSE ET AL .
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Statistical analysis . Data were compiled and analyzed by
Dixon Statistical Associates . All data were verified by dou-
ble entry . Changes in vital signs, ECG, physical examina-
tion, chamber opacification and endocardial delineation
were evaluated by analysis of variance among baseline,
study and follow-up assessments . The Fisher exact test was
also used to assess changes . Changes were considered
significant at p < 0 .05. In patients reporting a potential
adverse device effect, changes in laboratory data were
evaluated by comparing each baseline laboratory measure-
ment with the result at the 24-h follow-up study by using the
following measurement categories : below, within and above
normal range . The McNemar chi-square test was used to
determine the significance of any changes in laboratory data .
Results
Left ventricular opacification . In 106 (61%, Group A) of
the 175 patients enrolled, the investigators scored interme-
diate or better (k-2
. 0 chamber opacification with the initial
dose of 0.08 inl1g . In these patients, subsequent doses of
0.14 and 0.08 ml/kg produced >_2 .+ opacification in 99% and
92%, respectively . The independent reviewers, who were
blinded to the protocol, scored this level of chamber opaci-
fication in 82%, 91% and 80% of Group A patients at these
three doses, respectively . Overall, the independent review-
ers scored ?2+ with at least one of the doses in 93% of
patients in this group
.
Group B comprised the 69 patients (39%) whose initial
contrast dope of 0.08 ml/kg failed to produce L-2+ left
ventricular chamber opacification, according to the investi-
gators . Of these, 36 patients (52%) had intermediate or
better chamber opacification with the final, large bolus of
0.22 mUkg, as graded by the investigators . According to the
independent reviewers, 29 of the Group B patients (42%)
achieved this degree of opacification with the final bolus . For
the entire group of 175 patients, 81% demonstrated 2!2+ left
ventricular chamber opacification with at least one of the
contrast doses according to the investigators, whereas in the
judgment of the independent reviewers, the proportion was
74% .
A comparison of demographic, clinical, and historical
features between Groups A and B indicated that Group B
patients were older (p < 0
.001) and heavier (p < 0.04) than
Group A patients (Table 1) . The presence of cardiomyopa-
thy, mitral stenosis, other valvular heart disease or other
cardiac diagnoses did not correlate with efficacy
. However,
ejection fraction appeared to correlate with degree of opaci-
fication . In a subset of 51 patients (27 in Group A, 24 in
Group B), the ejection fraction was available from the
baseline echocardiogram or from a recent left ventricular
angiogram . The mean ejection, fraction in Group A patients
was 52% compared with 42% in Group B patients (p = 0
.03) .
Endocardial delineation. For each of the 175 study pa-
tients, the endocardium was "not well delineated" in at least
two of the six endocardial segments into which the baseline
"Six patients are not reported for all injections because no endocardial
segments were graded A at baseline by the independent reviewers blinded to
the protocol . One patient is not reported for the first injection, and two
patients are not reported for the second injection because the echocardio-
phic images were not recorded and were therefore not available to the
independent reviewers . One patient did not have the third injection graded
and is not reported .
apical two- or four-chamber echocardiogram was divided .
For the group as a whole, improved endocardial definition
was scored in 145 patients (83%) with at least one of the
contrast doses, according to the investigators . According to
the independent reviewers, improved depiction was ob-
served in 75% of patients .
In 96 (91%) of the 106 patients constituting Group A
(Table 2), the investigators found that the initial 0 .08-ml/kg
contrast dose improved endocardial depiction in at least one
segment that was not well delineated on the baseline
echocardiogram . Improved endocardial definition was
scored in 92% of patients with each of the ensuing doses of
0,14 and 0 .08 mlikg. As graded by the independent review-
ers, improved border depiction occurred in 81%, 88% and
84%, respectively, of the patients at the three doses .
Of the 69 Group B patients (Table 3), the investigators
graded improved endocardial delineation in at least one
poorly defined segment in only 16 (23%) after administration
of the initial dose of contrast agent . The final bolus of
0.22 mUkg enhanced endocardial definition in such segments
in 44 patients (64%)
. The independent reviewers reported
improved end ial imaging in 2 of patients with the
initial dose and in 56% with the final bolus .
WON nt . Before the study, investigators
were questioned with regard to their confidence in describing
regional left ventricular wall motion on the baseline echocar-
di . In 87 (48%) of the 175 patients, the investigators
were not confident about assessing regional wall motion . In
67
(77%) of these 87 patients, administration of contrast
'See footnote for Table 2.
agent increased the investigators' confidence level . Addi-
tionally, in the group of 88 patients with whom the investi-
gators were confident in interpreting regional wall motion on
the baseline echocardiogram, contrast administration further
improved that confidence level in 56 patients (57%) .
Vid ensitometry . Figure 4 shows the results of a linear
regression analysis of normalized videodensitometry versus
visual grading of left ventricular chamber opacification as
graded by investigators, independent reviewers and all in-
terpreters combined . There was a strong correlation be-
tween videodensitometric and subjective assessments for all
three groups (r = 0.895, 0.96 and 0.97, respectively) .
Safety evaluation. Adverse effects were clinically insig-
nificant and transitory. The most commonly reported symp-
tom was altered taste sensation, occurring in 13 patients .
Dysgeusia appeared shortly after contrast agent injection
and resolved within I min of its appearance . Other reported
symptoms occurred less often, and the investigators did not
attribute them to contrast administration because they oc-
Figure 4. Normalized videodensitometry (Y) versus chamber opaci-
fication grade (X) (investigators and independent reviewers blinded
to the protocol). The linear regression equation is Y = 0 . 193X +
0.122,r=0.97 .
0 .®
z
0
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Table 3. Group B: Improvement of Left Ventricular
Border Delineation
O
	
1 1.5 2 ' .5
3
Opacification Grade
L_	
Investigators
(n = 69)*
Independent
Reviewers
(n = 66)*
First dose (0 .08 ml/kg)
Improvement (no.)
~:2+
16 19
<2+ 53 47
Efficacy (%) 23 29
Final dose (0.22 mUkg)
Improvement (no.)
44 37
`2+ 25 29
Efficacy (Vi')
64 56
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Table 2 . Group A: Improvement of Left Ventricular
Border Delineation
Investigators
(n = 106)*
Independent
Reviewers
(n = 99)*
First dose (0.08 mUkg)
Improvement (no.)
z2+
96
80
<2+
9 19
Efficacy (%)
91
81
Second dose (0.14 ml/kg)
Improvement (no
.)
2+
97 86
<2+
8 12
Efficacy (%)
92
88
Final dose (0.08 mUkg)
Improvement (no .)
2!2+ 98 84
<2+
8 is
M acy ( ) 92 84
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curred after the 30-min observation period after injection,
Eight patients had subtle changes on physical examination at
the end of this observation period . These were considered to
be clinically insignificant, consisting primarily of rales that
cleared with cough. Twelve patients developed minor ECG
changes primarily consisting of transitory, nonspecific repo-
larization changes. No trends were apparent except for the
appearance of occasional, isolated atrial and ventricular
premature depolarizations . Vita! signs were stable through-
out the study and follow-up periods .
Discussion
Although a detailed description of regional wall motion is
an inherent part of the echocardiographic examination,
incomplete imaging of the eadocardium occurs in 10% to
15% of patients in a large series (1-3). Previous reports have
indicated that endocardial dropout is a frequent phenomenon
on routine echocardiography, with the anterior wall and
apex most frequently affected (8-10) . These observations
were reinforced by the work of Broderick et al . (11), who
specifically attempted to image the entire left ventricular
endocardium . In 30% of their patients, at least one endocar-
dial segment could not be imaged . Moreover, complete
endocardial delineation in both apical two-chamber and
apical four-chamber views could be accomplished in only 18
(36%) of their 50 study patients . The importance of complete
endocardia! depiction has increased in an era when innova-
tive therapies (e.g., reperfusion therapy in acute myocardial
infarction) can be expected to exert a greater impact on
regional wall motion .
Several echocardiographic contrast agents have been
evaluated in an effort to enhance the depiction of the left
ventricular chamber endocardium interface . These include
agitated saline solution (12,13), indocyanine green (14),
Renografin (4), saccharide microparticles (5,6) and hand-
prepared albumin microspheres (7) . These agents are limited
by one or more of the following : instability of the preparation
over time, lack of reproducibility of results or inability to
traverse the pulmonary vasculature, necessitating injection
into the left heart chambers . Berwing and Schlepper (15)
reported their experience with the intravenous injection of
oxypolygelatin plasma substitute that had been mixed with
air to form soluble microbubbles . Ninety-five percent of
their patients exhibited left atrial and ventricular opacifica-
tion with this agent . In a series of relatively small volumes of
contrast, Feinstein et al . (16) reported on the safety and
efficacy of intravenously administered Albunex, a stable
solution of air-filled microspheres created by sonication of
5% human serum albumin . The current study undertook to
evaluate the safety and efficacy of this agent in opacifying
the left ventricular chamber and enhancing endocardial
definition in patients whose noncontrast echocardiograms
produced incomplete endocardial imaging.
Left ventricular chamber opacification . Our findings con-
firm that the peripheral intravenous administration of soni-
CROUSE ET AL .
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cated human serum albumin restifts in transpulmonary pas-
sage of the agent and its consequent appearance in the left
heart chambers . Left ventricular opacification by contrast
agent injection resulted in a clearer definition of the endo-
cardial border . It bears emphasizing that the patients en-
rolled in this study were those who may have benefited most
from contrast agent administration, namely, those who have
routine echocardiograms with incomplete endocardial depic-
tion . Despite selecting only such patients with technically
difficult routine examinations, most exhibited at least inter-
mediate left ventricular chamber opacification with contrast
agent. There was generally good agreement between inves-
tigators and independent reviewers, and quantitative video-
densitometric analysis correlated very closely with the de-
gree of left ventricular chamber opacification, as graded by
both groups of interpreters . As with opacification, there was
also good agreement between these groups in their assess-
ments of the effect of contrast agent administration on
endocardial imaging . As a result of improved, more com-
plete definition of the endocardium, the investigators re-
ported a greater subjective sense of confidence in describing
regional wall motion in most patients, even when they
expressed confidence in their interpretation of the baseline,
noncontrast echocardiograms .
Comparison of patients who had at least intermediate left
ventricular chamber opacification produced by contrast
agent administration and those who did not indicates that
advanced age and overweight were more prevalent in the
latter group . No relation between degree of opacification and
underlying cardiac diagnosis was found . Retrospective sub-
group analysis according to ejection fraction suggests that in
patients with lower ejection fractions, contrast agent was
less likely to opacify the left ventricle . Possible explanations
for this finding include the delivery of a lower intensity bolus
of contrast agent because of low output states and low flow
volumes entering regions of asynergy in patients with seg-
mental wall motion abnormalities . Confirmation of this ob-
servation must await prospective testing .
Safety. At the doses used in this study, the administra-
tion of sonicated human serum albumin is safe and well
tolerated. Transitory dysgeusia was the most frequently
reported symptom. Other symptoms were infrequently re-
ported and were thought not to be attributable to the contrast
agent. Brief, clinically insignificant changes in the physical
examination and ECG were observed at a very low fre-
quency. Feinstein et al
. (16) also reported a very low
incidence of adverse effects produced by this agent, although
the doses of contrast agent were smaller in that study .
Conclusions
. The results of this multicenter trial indicate
that sonicated human serum albumin, when administered
intravenously, is a safe, effective echocardiographic contrast
agent that, when used in patients whose routine echocardio-
grams provide limited endocardial imaging, enables a more
complete depiction of the endocardial border and, thereby, a
more confident interpretation of regional wall motion . The
potential applicability of this agent in specific settings-for
1500
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example, evaluation of reperfusion therapy in acute myocar-
dial infarction, stress echocardiography and the design of
automated edge-detection systems-represents promising
areas for future investigation .
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